Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anas Younes

Showing results (11-20 of 310) with videos related to

Pageof 31
Sort By:
Cancer Journal (Sudbury, Mass.)|August 1, 2020
Special StatementAnas Younes
Nature Reviews. Clinical Oncology|December 15, 2010
Beyond chemotherapy: new agents for targeted treatment of lymphomaAnas Younes
Hematology/Oncology Clinics of North America|November 28, 2016
Promising Novel Agents for Aggressive B-Cell LymphomaAnas Younes
Clinical Lymphoma|January 13, 2004
A phase II study of heat shock protein-peptide complex-96 vaccine therapy in patients with indolent non-Hodgkin's lymphomaAnas Younes
Hematological Oncology|June 19, 2013
XIV. The rationale for combining targeted and biological anti-lymphoma drugsAnas Younes
Current Molecular Medicine|November 25, 2005
Angiogenesis in lymphoma: a short reviewAnas Younes
Hematological Oncology|June 11, 2015
XII. Therapeutic exploitation of autologous T-cell activation in B-cell lymphomaAnas Younes
Journal of Oncology Practice|February 13, 2016
Targeting Programmed Death 1/Programmed Death Ligand 1 in Lymphoma: A Game ChangerAnas Younes
Hematology. American Society of Hematology. Education Program|December 17, 2009
Novel treatment strategies for patients with relapsed classical Hodgkin lymphomaAnas Younes
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 23, 2012
Early-stage hodgkin's lymphoma: in pursuit of perfectionAnas Younes
Pageof 31

Showing results (11-20 of 310) with videos related to

Sort By:
Pageof 31
Cancer Journal (Sudbury, Mass.)|August 1, 2020
Special StatementAnas Younes
Nature Reviews. Clinical Oncology|December 15, 2010
Beyond chemotherapy: new agents for targeted treatment of lymphomaAnas Younes
Hematology/Oncology Clinics of North America|November 28, 2016
Promising Novel Agents for Aggressive B-Cell LymphomaAnas Younes
Clinical Lymphoma|January 13, 2004
A phase II study of heat shock protein-peptide complex-96 vaccine therapy in patients with indolent non-Hodgkin's lymphomaAnas Younes
Hematological Oncology|June 19, 2013
XIV. The rationale for combining targeted and biological anti-lymphoma drugsAnas Younes
Current Molecular Medicine|November 25, 2005
Angiogenesis in lymphoma: a short reviewAnas Younes
Hematological Oncology|June 11, 2015
XII. Therapeutic exploitation of autologous T-cell activation in B-cell lymphomaAnas Younes
Journal of Oncology Practice|February 13, 2016
Targeting Programmed Death 1/Programmed Death Ligand 1 in Lymphoma: A Game ChangerAnas Younes
Hematology. American Society of Hematology. Education Program|December 17, 2009
Novel treatment strategies for patients with relapsed classical Hodgkin lymphomaAnas Younes
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 23, 2012
Early-stage hodgkin's lymphoma: in pursuit of perfectionAnas Younes
Pageof 31